Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Roche Names O’Day Pharma Head as Soriot Becomes AstraZeneca CEO

Aug. 28 (Bloomberg) -- Roche Holding AG named Daniel O’Day head of its pharmaceuticals division to succeed Pascal Soriot, who is leaving the Swiss drugmaker to become chief executive officer of AstraZeneca Plc.

O’Day will begin the position Sept. 1, the Basel, Switzerland-based company said today in an e-mailed statement. Roland Diggelmann will succeed O’Day as head of diagnostics, Roche said.

Diggelmann is currently head of the Asia-Pacific region for the diagnostics unit.

To contact the reporter on this story: Thomas Mulier in Geneva at

To contact the editor responsible for this story: David Risser at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.